C07K 16/08
Against material from viruses
Official title: against material from viruses
C07K16/08 (Against material from viruses) appears on 3,399 US grants and 5,157 published applications in this corpus.
Search patents in C07K- Granted patents
- 3,399
- Published applications
- 5,157
- Assignees
- 2,050
- Inventors
- 9,471
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 3 | 0 |
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 5 | 0 |
| 1985 | 3 | 0 |
| 1986 | 8 | 0 |
| 1987 | 14 | 0 |
| 1988 | 17 | 0 |
| 1989 | 21 | 0 |
| 1990 | 11 | 0 |
| 1991 | 15 | 0 |
| 1992 | 24 | 0 |
| 1993 | 32 | 0 |
| 1994 | 18 | 0 |
| 1995 | 24 | 0 |
| 1996 | 41 | 0 |
| 1997 | 73 | 0 |
| 1998 | 89 | 0 |
| 1999 | 75 | 0 |
| 2000 | 75 | 0 |
| 2001 | 65 | 13 |
| 2002 | 50 | 73 |
| 2003 | 54 | 111 |
| 2004 | 34 | 122 |
| 2005 | 43 | 103 |
| 2006 | 57 | 122 |
| 2007 | 54 | 105 |
| 2008 | 54 | 101 |
| 2009 | 59 | 124 |
| 2010 | 75 | 179 |
| 2011 | 61 | 163 |
| 2012 | 95 | 186 |
| 2013 | 92 | 161 |
| 2014 | 133 | 205 |
| 2015 | 98 | 188 |
| 2016 | 142 | 239 |
| 2017 | 143 | 217 |
| 2018 | 180 | 249 |
| 2019 | 196 | 258 |
| 2020 | 184 | 290 |
| 2021 | 185 | 305 |
| 2022 | 156 | 292 |
| 2023 | 157 | 410 |
| 2024 | 190 | 441 |
| 2025 | 166 | 304 |
| 2026 | 122 | 196 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-196 Oct 2026US 12,753,417 B2The Feinstein Institutes for Medical Research
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Compositions and methods related to human neutralizing antibodies to hepatitis B29 Sep 2026US 12,747,283 B2The Rockefeller University
- Compositions and methods for treatment of neurological disorders8 Oct 2026US 2026/0308614 A1Board of Regents, The University of Texas System
- Click chemistry assisted cell surface engineering for restoring lentivirus entry8 Oct 2026US 2026/0308632 A1The Children’s Hospital of Philadelphia
- Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf)1 Oct 2026US 2026/0295009 A1Partner Therapeutics, Inc.
- Asymmetric circular tandem repeat proteins1 Oct 2026US 2026/0297166 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Methods and compositions comprising purified recombinant polypeptides1 Oct 2026US 2026/0297179 A1Genentech, Inc.
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polynucleotides encoding improved humanized immunoglobulins1,258US 5,693,761 AProtein Design Labs, Inc. · 1997